Tag:
Tysabri
Latest Headlines
Latest Headlines
Amid deal frenzy, Elan rejects latest buyout bid from Royalty Pharma
Elan's ($ELN) board of directors has rebuffed the most recent acquisition offer from Royalty Pharma, saying that the bid valued at $6.4 billion undervalues the Ireland-based biopharma group and robs investors of the best value for their shares. With its eyes on Elan's prized Tysabri royalty stream, Royalty made the most recent $12.50-per-share offer on Monday.
UPDATED: Royalty Pharma drops $12/share cash offer in lap of Elan shareholders
The board of Elan recently waved off an $11-a-share buyout offer from Royalty Pharma as "highly conditional" and told the group to come back when it had something more concrete to talk about. Now Royalty is back with a rock-solid, all-cash $12-a-share offer and a bit of dismissiveness in its own talk.
Elan investors approve share buyback but still must decide on buyout
Being a shareholder in Elan these days is a bit like taking a multiple choice quiz in an advanced MBA class.
Elan closes $3.25B Tysabri deal and preps for biotech deal spree
Elan has wrapped up its $3.25 billion deal to sell its stake in Tysabri to Biogen Idec and begun to pivot to the next chapter in its storied journey, ready to unleash a burst of new acquisitions after it hopes to bury a buyout offer from an unwelcome suitor.
Biogen prices Tecfidera below oral MS rival Gilenya
Biogen Idec's ($BIIB) newly approved Tecfidera has a wholesale price of $54,900 per year, the biotech giant revealed on Friday. With the U.S. market debut of the oral multiple sclerosis drug set for Monday, Biogen plans to hit the market for MS pills with a lower price than Novartis' ($NVS) Gilenya, which is arguably the company's top competition.
Biogen's Tecfidera expected to hit the MS market running
The FDA gave its final blessing to Biogen Idec's much-anticipated multiple sclerosis pill Tecfidera. It's the third oral MS treatment to hit a market long limited to injectable drugs. But Biogen believes--and many analysts agree--that Tecfidera can surpass its oral competitors, and quickly.
Elan woos investors with a special dividend plan for Tysabri
Elan ($ELN) has found a way to sweeten the pot for investors who may be tempted to sell their shares to a royalty group offering to cash them out following the $3.25 billion Tysabri deal.
Royalty Pharma offers Elan investors a chance to cash out with $6.55B deal
A royalty investment group believes it can one-up Elan CEO Kelly Martin on a strategy for the company's next chapter. Royalty Pharma today offered $6.55 billion to simply buy out the company, giving investors a choice between cash in hand and trusting Martin to invest the $3.25 billion Tysabri windfall wisely.
Elan lines up biotech deals as it preps for $3B Tysabri windfall
Dublin-based Elan has told investors how it plans to play the first two rounds in a $3.25 billion game set up by the sale of Tysabri. In a statement this morning the biotech company said it will use the first $1 billion in a share buyback aimed at returning some of the money to investors
Elan shareholders to get taste of $3.25B windfall
Some shareholders started grumbling that they would like to get their hands on the windfall as soon as they learned Elan would sell its key asset, multiple sclerosis drug Tysabri, to Biogen Idec ($BIIB) for $3.25 billion.
